NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Linda is saying that no one wants to release their patient level data and the FDA guidance says that is the ideal way to move forward. There was no way for NWBO to get patient level data to compare with their own. Pretty simple really.

Yet, Medicenna has no problem running a P3 in rGBM that uses patient level data for their ECA.

It is as simple as that,